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Objectives. To investigate which skills and competence are imperative to assure optimal eﬀectiveness and safety of procedural
sedation (PS) in children and to analyze the underlying levels of evidence. Study Design and methods. Systematic review of
literature published between 1993 and March 2009. Selected papers were classiﬁed according to their methodological quality and
summarized in evidence-based conclusions. Next, conclusions were used to formulate recommendations. Results. Although the
safetyproﬁlesvaryamongPSdrugs,thepossibilityofpotentiallyseriousadverseeventsandthepredictabilityofdepthandduration
of sedation deﬁne the imperative skills and competence necessary for a timely recognition and appropriate management. The level
ofeﬀectivenessismainlydeterminedbytheabilitytoapplytitratablePS,includingdeepsedationusingshort-actinganestheticsfor
invasive procedures and nitrous oxide for minor painful procedures, and the implementation of non-pharmacological techniques.
Conclusions. PS related safety and eﬀectiveness are determined by the circumstances and professional skills rather than by speciﬁc
pharmacologic characteristics. Evidence based recommendations regarding necessary skills and competence should be used to set
up training programs and to deﬁne which professionals can and cannot be credentialed for PS in children.
1.Introduction
Invasive diagnostic procedures are a part of daily pediatric
practice. Many of these procedures are painful, stressful, and
impossible to perform without immobilizing the patient.
Therefore, procedural sedation (PS) is required to enable
these procedures to be performed. PS can be deﬁned as the
use of sedative, analgesic, or dissociative drugs in order to
provide anxiolysis, analgesia, sedation, and motor control
during painful or unpleasant procedures [1].
Sinceanesthesiologistscannotcoverthegrowingdemand
for PS, nonanesthesiologists have organized their own PS
strategies [2, 3]. Historically, this resulted in a wide range
of drugs and techniques for use in pediatric PS, involving a
large variance of sedation levels, sedation level predictability,
eﬀectiveness, and associated risks. However, by the end of
last century, PS by nonanesthesiologists was increasingly
criticized by anesthesiologists for neglecting transparency
andstandardsafetyprecautions.Therearestrongindications
that within this criticism, a source could be found for
PS-related accidents [4, 5]. About a decade ago, dedicated
nonanesthesiology specialists, who recognized the urgent
need to improve the safety and quality of PS in children,
joined the initial criticism by anesthesiologists, pointing
at the safety problems of PS by the untrained. In order
to prevent PS-related tragedies, guidelines on PS were
published [1, 6–10]. In summary, these guidelines specify
safety precautions that include the assessment of the risk
of sedation prior to PS, informed consent, guidelines on
proper fasting status, appropriate monitoring, recovery stan-
dards, appropriate rescue facilities, and speciﬁc professional
skills and competence. Generally recommended skills and2 International Journal of Pediatrics
competence are: the ability to perform a preprocedural
risk analysis, practical knowledge and experience of applied
sedatives, the ability to implement the necessary monitoring
and surveillance, the ability to recognize and interpret
sedation levels, and the ability to immediately recognize and
adequately treat any unwanted side eﬀects or complications,
particularly hypoventilation and airway obstruction. These
recommendations are mainly based on indirect evidence,
expert opinion, “common sense”, and widely accepted safety
rules for general anesthesia. The adoption of a uniform and
systematic practice is associated with a signiﬁcant reduction
in adverse events during anesthesia [11]. Similarly, there is
strong evidence that implementation of published guidelines
leads to safer and more eﬀective PS [12–15].
However, despite the availability of guidelines, PS prac-
tice is still unsafe in many settings and adherence to
guidelines among nonanesthesiologists has been reported
to be low [16, 17]. It has been argued that guidelines
on PS produced by consensus between anesthesiologists
(rather than on evidence-based guidelines by the clinicians
themselves) have caused confusion and variation in practices
[3].
Recent papers focus increasingly on the duty to deliver
eﬀective PS, not only from a procedural point of view (i.e.,
guaranteeing predictable procedural success and timing) but
also from a patient’s perspective (i.e., achieving optimal
procedural comfort and minimizing procedural stress and
failure) [18, 19]. Drugs traditionally used for PS (e.g.,
chloral hydrate, midazolam, barbiturates, and lytic cocktails)
are associated with a substantial risk of procedural failure,
discomfort, extended sedation times, and deeper sedation
levels than intended with associated safety risks [20, 21].
Patient comfort is currently considered a primary goal of
procedural sedation [22]. It has been argued that young
children who are anticipated to suﬀer from substantial
emotional distress need a titrated form of PS, including
deep sedation, in order to have a successfully completed
procedure, and to avoid major psychological trauma to
the child, the family, and healthcare staﬀ [23, 24]. The
application of forced immobilization by physical restraint
is increasingly considered as inhumane and unacceptable in
nonlifesaving procedures [22, 25].
We searched the literature for available evidence on
essential professional skills and competence required for
eﬀective and safe PS in children. Results were used to deﬁne
evidence-based recommendations on the skills and compe-
tence a professional entrusted with PS should minimally
possess, in order to be able to perform PS in children safely
and eﬀectively.
2. Methods
Literature was searched and selected by a multidisciplinary
panel of the Dutch Institute for Health Care Improve-
ment CBO, involved in the development of an evidence-
based guideline on PS using the Evidence-Based Guideline
Development (EBRO) methodology. Systematic searches
were done in Medline, Cochrane Library, and Embase,
using the Medical Subject Heading (MESH) search terms
“Conscioussedation/all”,“Moderatesedation/all”,and“Deep
sedation/all” and the free search-terms “sedation”, “pediatric
sedation” and “procedural sedation”, in title or abstract.
The search was limited to papers published between 1993
and March 2009, in 4 languages (Dutch, English, French,
and German) and to human subjects aged 0–18 years.
Results were systematically and repeatedly combined with
the MESH-term “Drug Toxicity” and the MESH-terms
of drugs, drug combinations, and drug groups available
for PS (chloral hydrate, (lytic) cocktails, promethazine,
chlorpromazine, pentobarbital, thiopental, midazolam, fen-
tanyl, meperidine, ketamine, propofol, dexmedetomidine,
remifentanil, nitrous oxide, opioids, benzodiazepines, anti-
histaminic, antipsychotics, barbiturates, nitrous oxide, and
anesthetics). For all drugs, speciﬁc searches were done
using the MESH subheading “adverse eﬀects”. Additional
combined searches were done using search terms for safety,
eﬀectiveness, and non-pharmacologic methods (hypnosis,
distraction techniques, and play therapy). Textbooks and
reference tables were systematically searched for additional
papers.
Before inclusion in the pool of studies to be reviewed,
all papers obtained were analyzed by the multidisciplinary
panel for relevance and accuracy of deﬁnitions of safety and
eﬀectiveness.
In accordance with the EBRO methodology, selected
papers were classiﬁed according to their methodological
quality and strength of evidence: A1: systematic review
including at least two independent A2-level studies, A2:
randomized, double blinded comparative clinical trial of
good quality and substantial size, B: comparative study,
including retrospective cohort study and case-controlled
trial, but not having all characteristics of an A2 study, C:
noncomparative studies, and D: expert opinion. Findings
from literature were summarized in conclusions. These
conclusions were classiﬁed in 4 levels. Level 1: conclusion
based on one A1 study or on at least two independent A2
studies, level 2: conclusion based on one A2 study or on at
least two independent B studies, level 3: conclusion based on
one B or C study, and level 4: conclusion based on expert
opinion only. Finally, on the basis of the conclusions and
remaining considerations (nonclassiﬁed) recommendations
were formulated.
3. Results
3.1. Requisite Skills and Competence to Guarantee Optimal
Safety. Many studies were found claiming the safety of all
kinds of PS drugs in a variety of settings but usually in
a limited series of patients. However, given an estimated
incidence of severe adverse events of about 1/10000, the
majority of these studies are insuﬃciently powered to prove
such conclusion [18]. Most studies use vague deﬁnitions for
the adverse reactions they report and consider the absence
of directly life-threatening events as synonym for “safe”. In
more recent observational studies on PS, the study setting
is usually a strictly controlled, well-equipped, well-trained,International Journal of Pediatrics 3
and dedicated sedation team, which may diﬀer appreciably
from common settings in many practices around the world.
Finally, well-designed controlled prospective studies in
nonanesthesiologists analyzing the relationship between the
level of professional skills/competence and the safety of PS
are nonexistent. Therefore, evidence on this subject must be
gathered in an indirect way. To do so, the following rationale
was followed. At ﬁrst, published critical analysis of PS-
related incidents might elucidate the requisite competence
and skills for PS. Next, the level of skills and competence
professionals must achieve with regard to safety are likely
to be determined by (1) the probability that a medicine
may have undesirable adverse eﬀects which require speciﬁc
recognition and treatment, and (2) the predictability of the
depth and duration of sedation of a medicine. The latter
is important since unexpected deep sedation is associated
with a higher rate of adverse events [21]. Out of all retrieved
studies reporting PS-related adverse events, only those were
selected for this systematic paper that reported the incidence
of adverse events in large numbers of patients (>±1000),
or that had studied adverse events following the use by
nonanesthesiologists of the anesthetics propofol, ketamine,
dexmedetomidine, remifentanil, and nitrous oxide.
3.1.1. Retrospective Critical Incident Analysis of PS-Related
Adverse Events and Outcomes. In 2000, Cot´ e published, in
two separate papers, a retrospective critical incident analysis
of adverse sedation events in pediatrics, as reported to the
American Food and Drug Administration between 1969 and
1996. 95 incidents were reported, 51 resulting in death,
9 in permanent neurological injury, and 21 in prolonged
hospitalization. Signiﬁcant contributing factors were: “out of
hospital” locations, inappropriate monitoring of physiolog-
ical parameters, inadequate resuscitation skills, inadequate
presedation medical evaluation, and inadequate recovery
procedures. No particular medication was associated with
a higher risk, except that overdosing and drug interactions
(particularly when 3 or more drugs were used) were
associated with mortality [4, 5]. Although the safety proﬁle
and the margins of safety vary among drugs, Cot´ e showed
that PS-related safety is determined by circumstances and
professional skills, rather than by speciﬁc pharmacological
characteristics. Professionals who do not have the requisite
competence to recognize and treat the potential PS-related
complications constitute a signiﬁcant risk factor for the
occurrence of fatal complications or complications causing
permanent harm to the patient (Level 3 conclusion [4, 5]).
3.1.2. Reported Data on PS-Related Adverse Events. The
studies stated below are summarized in Tables 1 and 2.
Adverse Eﬀects of Commonly Used Nontitratable Sedatives.
A retrospective study by Sanborn et al. of 16467 seda-
tions during imaging procedures in children using chloral
hydrate, midazolam, fentanyl, or pentobarbital found 70
(0.4%) respiratory incidents: desaturation only (N = 58),
aspiration (N = 2), and airway obstruction requiring airway
intervention (N = 10). The main risk factors were an
underlyingrespiratoryproblemandtheuseofmorethanone
sedative [27].
A prospective study by Malviya et al. in 1140 children,
of which the majority were sedated with chloral hydrate for
diagnostic imaging, showed a 5.5% incidence of respiratory
complications leading to oxygen saturation of <90%: respi-
ratory depression (4.7%), airway obstruction (0.6%), and
apnea (0.17%). The risk of complications was signiﬁcantly
greater for more seriously ill children and for children less
than one year old [28].
A risk analysis by Hofmann et al. based on prospectively
collected data of 950 sedations using chloral hydrate, mida-
zolam, fentanyl, pentobarbital, ketamine, or cocktails of 3
or more agents, identiﬁed 27 sessions (2.8%) in which a
serious adverse event occurred: deep desaturation (N = 9),
airway obstructions (N = 5), apneas (N = 3), aspirations
(N = 2), hypotension, bradycardia (N = 2), or excessively
deep or prolonged sedations (N = 6). Signiﬁcant risk factors
were the absence of a systematic risk assessment, a failure to
follow safety guidelines, deep sedation, the simultaneous use
of multiple agents, and the use of chloral hydrate [13].
A prospective international multicentre study of 30037
sedations by speciﬁcally trained professionals working in
dedicated PS teams reported low incidences of major adverse
events: desaturation (SatO2 < 90%) 1.57%, stridor 0.04%,
laryngospasm 0.04%, apnea 0.24%, excessive airway secre-
tions0.41%,andvomiting0.47%.Theattendingprofessional
could adequately treat all complications. Cardiopulmonary
resuscitation was necessary in one case. Anesthesiologists
(19%), emergency physicians (28%), and intensivists (28%)
administered the sedations. The most frequently used seda-
tives were propofol (50%), midazolam (27%), ketamine
(14%), chloral hydrate (12%), pentobarbital (13%), and
opiates (10%) [36].
Mason et al. reported in three separate comparative
studies the adverse events of oral and intravenous (IV)
pentobarbital used for PS in diagnostic imaging or nuclear
medicine. Potentially severe adverse events like oxygen
desaturation occurred extremely rare (<1%). Compared to
oral chloral hydrate and intravenous pentobarbital, oral pen-
tobarbital is associated with signiﬁcantly less desaturations
(resp., 1.6% versus 0.2% and 0.9% versus 0.2%) [35, 38, 39].
A retrospective study by Roback et al. in 2500 successive
children undergoing PS in an emergency department (ED)
showed that the incidence of respiratory complications
depended on the medication used: 5.8% for midazolam,
6.1% for ketamine, 10% for ketamine + midazolam, and
19.3% for midazolam + fentanyl [33].
A prospective study by Newman et al. of 1341 PS
sessions in children in an ED showed an incidence of serious
complications of 11.9% (96,2% hypoxia, 1,3% hypotension,
and2,5%stridor).92%ofthecomplicationsoccurredduring
the actual procedure, whereas the rest occurred after the
procedureupto40minutesafterthelastdoseofsedative.The
risk of complications depended strongly on the medication
used: midazolam 1.4%, ketamine + midazolam + atropine
9.8%, and midazolam + fentanyl 21.5% [34].
Another ED study by Pena and Krauss of 1180 succes-
sive children, using intravenous medicines (midazolam +4 International Journal of Pediatrics
Table 1: Overall conclusions regarding the relation between professional competence/skills and PS-related safety.
Nr Conclusion Quality level
(1)
Serious PS related adverse events occur more frequently
(I) In children with an underlying disease. Level 1
(A1) Green et al. 2009 [30]
(B) Sanborn et al. 2005 [27], Cravero et al. 2009 [26]
(C) Malviya et al. 1997 [28], Vespasiano et al. 2007 [29]
(II) If multiple sedatives are used Level 1
(A1) Green et al. 2009 [30]
(B) Hoﬀman et al. 2002 [13], Pitetti et al. 2003 [32], Sanborn et al. 2005 [27], Cravero et al. 2009 [26]
(C) Gall et al. 2001 [31]
(III) In young children Level 1
(A1) Green et al. 2009 (<2 years) [30]
(B) Cravero et al. 2009 (<6m o n t h s )[ 26]
(C) Malviya et al. 1997 (<1 year) [28], Gall et al. 2001 (<1 year) [31]
(IV) In certain drugs compared to others:
(IV.1) The combination of a benzodiazepine with an opiate (e.g., midazolam + fentanyl) is associated with a Level 2
higher risk of respiratory complications (21–23%) compared to the use of midazolam alone or ketamine
with midazolam.
(A2) Yildizdas et al. 2004 [8]
(B) Pitetti et al. 2003 [32], Roback et al. 2005 [33], Newman et al. 2003 [34]
(IV.2) Oral pentobarbital is associated with less adverse events compared to oral chloral hydrate Level 3
(B) Mason et al. 2004 [35]
(IV.3) In comparison with ketamine, midazolam and ketamine + midazolam, midazolam + fentanyl and Level 2
propofol generate a higher risk of hypoventilation and desaturation.
(A2) Yildizdas et al. 2004 [8]
(2)
Serious PS-related adverse events occur less frequently if speciﬁcally trained professionals working in dedicated Level 2
teams perform sedation according to international guidelines.
(B) Barbi et al. 2003 [12], Hoﬀman et al. 2002 [13], Cravero et al. 2009 [26]
(C) Vespasiano et al. 2007 [29]
fentanyl N = 391, midazolam N = 67, fentanyl N =
21, ketamine N = 40, pentobarbital N = 93, lorazepam
N = 9, or midazolam + morphine N = 1), intramuscular
ketamine (N = 180), oral medicines (midazolam N = 62,
ketamine N = 2, chloral hydrate N = 122, diazepam
N = 1, and lorazepam N = 1), rectal chloral hydrate
N = 4),intranasalmedicines(midazolamN = 3,midazolam
+ sufentanil N = 25), and nitrous oxide (N = 168),
showed an overall complication incidence of 2.3% (N = 27).
The following complications occurred: desaturation < 90%
requiring intervention (N = 10), apnea (N = 1), larynx
spasm (N = 1), bradycardia (N = 1), stridor with vomiting
(N = 1), and 1 child started to vomit while being ventilated
with a mask/bag applied to treat desaturation. There was
no signiﬁcant diﬀerence in the incidence of adverse events
between the diﬀerent sedation medicines [37].
A prospective study by Pitetti et al. of 1244 sedations
in 1215 children in an ED showed an incidence of adverse
events of 17.8% including desaturation (N = 178), stridor
(N = 6), hypotension (N = 2), vomiting (N = 4 ) ,ar a s h
(N = 7), agitation (N = 9), hiccups (N = 3), and dizziness
(N = 3). An antidote had to be administered 6 times (3
ﬂumazenil, 3 naloxone) and 2 patients sedated with fentanyl
+ midazolam required respiratory interventions (one with
a Mayo cannula and one with mask/bag ventilation). The
risk of complications depended heavily on the medication
used. Patients sedated with midazolam + fentanyl had a
signiﬁcantly higher risk of adverse events (161/686 = 23.4%),
compared to patients who had been treated with midazolam
+ ketamine + atropine (24/277 = 8.6%) or IV midazolam
(1/65 = 1.5%) [32].
In a randomized controlled trial by Yildizdas et al.
of 126 children undergoing a PS for painful oncology
procedures, patients were randomly assigned for one of ﬁve
forms of intravenous PS: ketamine (1mg/kg), midazolam
(0.15mg/kg), ketamine + midazolam (1mg/kg + 0.1mg/kg),
midazolam + fentanyl (0.1mg/kg + 2micrograms/kg), and
propofol (2mg/kg). Patients were monitored through satu-
ration measurement and capnography. Patients sedated with
midazolam + fentanyl and with propofol had a signiﬁcantly
more desaturations and hypercapnia compared to the three
other groups. Desaturations were observed in 0%, 0%, 8%,
28%, and 52%, respectively, whereas hypercapnia was found
in 0%, 0%, 0%, 4%, and 12%, respectively [8].International Journal of Pediatrics 5
Table 2: Drug-speciﬁc conclusions regarding the relation between professional competence/skills and PS-related safety.
Nr Conclusion Quality Level
Nontitratable drugs intended for moderate to deep sedation
(1)
During PS, intended to moderate or deep sedation, with the use of benzodiazepines, chloral hydrate,
barbiturates, opiates, or combinations of these medicines, and during the subsequent recovery phase, there
exists a variable but real risk of potentially serious drug-induced adverse events. Especially the risk for
respiratory depression and/or airway obstruction necessitates speciﬁc skills and competence from the
professionals in charge in terms of recognition and treatment.
Level 2
(B) Hoﬀman et al. 2002 [13], Pitetti et al. 2003 [32], Sanborn et al. 2005 [27], Cravero et al. 2006 [36],
Roback et al. 2005 [33], Newman et al. 2003 [34], Pena et al. 1999 [37], Mason et al. 2001 [38],
Mason et al. 2004 [35], Mason et al. 2004 [39]
(C) Malviya et al. 1997 [28]
Propofol
(1)
During PS using propofol, there is a real risk of potentially serious drug-induced adverse events. Especially
the risk for respiratory depression and/or airway obstruction necessitates speciﬁc skills and competence from
the professionals in charge in terms of recognition and treatment.
Level 3
(B) Cravero et al. 2009 [26]
(c) Barbi et al. 2003 [12], Hertzog et al. 1999 [40], Hertzog et al. 2000 [41], Pershad and Godambe 2004
[42], Bassett et al. 2003 [43], Guenther et al. 2003 [44], Vespasiano et al. 2007 [29]
(2)
PS with propofol, including deep sedation, is equally safe in the hands of anesthesiologists and
nonanesthesiologists if the latter are well trained and part of dedicated sedation team.
Level 3
(B) Cravero et al. 2009 [26]
(C) Barbi et al. 2003 [12], Vespasiano et al. 2007 [29]
(3)
A deep PS using ketamine or propofol for examination of the upper airways, or for endoscopies of the upper
gastrointestinal system, carries a real risk of potentially serious complications (i.e., laryngospasm and deep
desaturation), which require speciﬁc skills and competence from the professionals in charge in terms of
recognition and treatment.
Level 3
(C) Barbi et al. 2003 [12], Green et al. 2001 [45]
Ketamine
(1)
During PS using ketamine, there is a small but real risk of potentially serious drug-induced adverse events.
Especially the risk for respiratory depression, airway obstruction and—infrequently—laryngeal spasm
necessitates speciﬁc skills and competence from the professionals in charge in terms of recognition and
treatment.
Level 1
(A1) Green et al. 2009 [30]
(C) Green et al. 2001 [45], Evans et al. 2005 [46], Meyer et al. 2003 [47], Cheuk et al. 2005 [48],
(2)
Independent risk factors for respiratory adverse events during a PS with the use of ketamine are high
intravenous doses, administration to children younger than 2 years or aged 13 years or older, and the
coadministration of anticholinergics or benzodiazepines.
Level 1
(A1) Green et al. 2009 [30]
Dexmedetomidine
(1)
Based on a limited published experience on the use of dexmedetomidine for PS by experienced professionals,
there seems to be a very small risk of potentially serious drug-induced adverse events. Respiratory events are
extremely rare and hemodynamic adverse events (i.e., bradycardia and hypotension) are mostly clinically
insigniﬁcant. Speciﬁc experience in dosing techniques, individual titration and avoiding dexmedetomidine
in those patients who may not tolerate hemodynamic ﬂuctuations seems to be associated with low risks.
Level 1
(A2) Koroglu et al. 2005 [49], Koroglu et al. 2006 [50]
(B) Mason et al. 2008 [51], Mason et al. 2008 [52]
(C) Berkenbosch et al. 2005 [53], Mason et al. 2006 [54], Ray and Tobias 2008 [55]
Remifentanil
(2)
During PS using remifentanil, there is a real risk of potentially serious drug-induced adverse events.
Especially the risk for respiratory depression and/or airway obstruction necessitates speciﬁc skills and
competence from the professionals in charge in terms of recognition and treatment.
Level 2
(A2) Keidan et al. 2001 [56]
(C) Litman 1999 [57], Litman 2000 [58]6 International Journal of Pediatrics
Table 2: Continued.
Nr Conclusion Quality Level
Nitrous Oxide
(1)
PS with nitrous oxide is associated with an extremely low chance of serious adverse events. Instant
discontinuation of gas ﬂow in case of respiratory depression is the most important rescue intervention.
Level 2
(B) Babl et al. 2005 [59], Babl et al. 2008 [60]
(C) Gall et al. 2001 [31]
(2)
Speciﬁc risks for adverse events during nitrous oxide administration are: Level 3
(I) A young age (<1 year old)
(C) Gall et al. 2001 [31]
II. Simultaneous use of other sedatives
(C) Gall et al. 2001 [31]
(3)
In patients sedated with nitrous oxide, there exists no signiﬁcant diﬀerence in median fasting time between
patients with and without emesis
Level 3
(B) Babl et al. 2005 [59]
(4)
Nitrous oxide 70% causes signiﬁcantly deeper sedation compared to nitrous oxide 50%. However, if
embedded in a comprehensive sedation program there exists no signiﬁcant diﬀerence in adverse events rates
between both regimens.
Level 3
(B) Babl et al. 2008 [60]
(C) Zier et al. 2007 [61]
Adverse Eﬀects of Propofol. Barbi et al.’s prospective study
concerned deep PS with propofol administered by nonanes-
thesiologists (1059 procedures in 827 children aged 0–21
years old: gastroscopies (N = 483), colonoscopies (N =
289), and painful procedures (N = 173). All sedating profes-
sionals had followed a speciﬁc training, including theoretical
and practical training on propofol, airway management,
mask/bagventilation,andresuscitation.Ofthe1059patients,
34 (12.6%) had a transient desaturation that resolved spon-
taneously. Deep desaturation with the need for mask/bag
ventilationwasrequiredin4/483patients(0.8%)undergoing
a gastroscopy, in 1/287 patients (0.3%) undergoing a painful
intervention, and in 0/289 patients (0.0%) undergoing a
colonoscopy. Laryngospasm occurred in 10/483 patients
(2.1%) who underwent a gastroscopy. In 24 of the 483 gas-
troscopies (4.9%), an anesthesiologist was urgently required.
In 13/24 cases (54.2%), this concerned assistance with the
laryngoscopic insertion of an endoscope, in 10/24 cases
(41.7%), the treatment of a laryngospasm and in 1/24 cases
(4.2%), assistance to deal with a serious esophageal bleed.
The trained professionals were able to manage adequately
all adverse events that occurred during colonoscopies and
painful interventions [12]. Propofol for PSA in children
administered by speciﬁcally trained nonanesthesiologists
has also been studied in pediatric oncology, radiology,
and emergency medicine. A retrospective study by Hertzog
et al. found that in 251 propofol sedations by pediatric
intensivists hypotension (50%) and respiratory depression
requiringtransientbag-valve-maskventilation(6%)werethe
most important adverse events [40]. A prospective study
by the same authors in 28 oncology patients, undergoing
50 sedations, showed similar results: transient hypotension
(64%) and partial airway obstruction (12%) were the
most important adverse events. Apnea requiring bag-valve-
mask ventilation occurred in 2% of procedures [41]. In a
retrospective case series by Pershad and Godambe (N =
52) of propofol PS in the ED, no patient required assisted
ventilation or developed clinically signiﬁcant hypotension.
The incidence of respiratory depression requiring airway
repositioning or supplemental oxygen was 5.8% [42].
Bassett et al. analyzed prospectively 293 propofol seda-
tions in children on an ED. Transient decrease in systolic
blood pressure without clinical signs of poor perfusion was
found in 92% of the patients. Nineteen patients (5%) had
hypoxia, 11 patients (3%) required airway repositioning or
jaw-thrust maneuvers, and 3 patients (0.8%) required bag-
valve-mask ventilation. No patient required endotracheal
intubation [43]. In a similar study by the same authors in 87
patients (291 sedation sessions), partial airway obstruction
requiring brief jaw-thrust maneuver was noted for 4% of
patient sedations. Transient apnea requiring bag-valve-mask
ventilation occurred in 1% of patient sedations [44].
Vespasiano et al. reported a prospective study on 7304
propofol sedations outside the operation room in 4464
children, undergoing MRI (42.8%), non-MRI diagnostic
imaging(22.5%),hematology/oncologyprocedures(26.2%),
or other procedures (10.5%). All sedations were performed
by pediatric intensivists according a sedation program that
was in adherence to the American Academy of Pediatrics
guidelines. The program was locally governed by a multi-
disciplinary committee with representation from anesthe-
siology, critical care, nursing, oncology, cardiology, and
emergency medicine. To assess the overall safety proﬁle
of propofol a speciﬁc quality audit tool was designed.
Hypotension (>25mmHg drop from baseline) occurred in
31.4% of the patients but was mostly without circulatory
compromise. High-volume ﬂuid therapy was necessary in
only 0.11% of cases. Infrequent respiratory adverse eventsInternational Journal of Pediatrics 7
were laryngospasm (0.27%), regurgitation without aspira-
tion (0.05%), regurgitation with aspiration (0.01%), and
bronchospasm (0.15%). Almost 5% of patients had an
oxygen desaturation (1.73% between 85–90%; 2.9% <
85%) while airway obstruction requiring an oral or nasal
airway occurred in 2% of cases. Unfortunately, ETCO2 was
not evaluated systematically in this study. Only 0.37% of
the patients needed bag-valve-mask ventilation because of
hypopnea and/or apnea. All side eﬀects could be managed
successfully by the sedation team. There were no cardiac
arrests. Patients with an abnormal airway (as deﬁned by
an airway score) were signiﬁcantly more likely to develop
oxygen desaturation or airway obstruction. None of the
intended procedures or sedations had to be aborted [29].
The multicentric Pediatric Sedation Research Consor-
tium (PSRC) collected prospectively data on 49836 propofol
sedations in children. The PSRC consists of anesthesiolo-
gists, pediatric medical subspecialists, emergency physicians,
pediatric intensivists, nurses, physician assistants, and health
care research personnel who seek to continuously improve
the quality, safety, eﬀectiveness, and cost of pediatric seda-
tion/anesthesia practice. Participants work in 37 diﬀerent
locations, including large children’s hospitals, children’s
hospitals within hospitals and general/community hospitals.
Following an initial study, the group meeting in this
consortium agreed on a collective mission statement regard-
ing pediatric procedural sedation. Decisions were based
on guidelines from the American Academy of Pediatrics,
American Society of Anesthesiologists, and American Col-
lege of Emergency Physicians regarding sedation/anesthesia
of pediatric patients, a review of the literature and the
consensus of the consortium members. Besides sharing a
common mission on PS, the PSRC is a data-sharing group:
all participators agree to perform periodic audits of records
to assure data and to maintain a prospective registry of all
patients receiving PS [36].
Transient O2 desaturation below 90% for more than 30
seconds occurred 154 times per 10000 propofol administra-
tions (1.5%). Central apnea or airway obstruction occurred
575 times per 10000 administrations (5.8%). Per 10000
encounters stridor occurred 50 times (0.5%), laryngospasm
96 times (0.96%), excessive secretions 341 times (3.4%),
and vomiting 49 times (0.49%). Aspiration occurred 4 times
during these 10000 sedation/anesthesia encounters (0.04%).
There were no deaths. Cardiopulmonary resuscitation was
required twice (0.02%). The sedating professionals could
manage all adverse events appropriately. In an unadjusted
analysis, the rate of pulmonary adverse events was not
diﬀerent for anesthesiologists versus other providers. Young
age (<6 months), fasting time <8 hours, ASA classiﬁcation
III or higher and concomitant use of opoids were all
signiﬁcantly related with a higher risk for respiratory adverse
events [26].
Adverse Eﬀects of Ketamine. Several authors studied
ketamine for PS during oncology procedures (lumbar
punctures, bone marrow punctures, and/or bone biopsies),
performed by non-anaesthesiologists. Evans et al. reported
an incidence of desaturation of 1.7% and no airway
obstruction during 119 sedation sessions [46]. Cheuk et al.
reported an incidence of desaturations of 8.7% during 369
sedation sessions. These desaturations only required brief
treatment with oxygen. No apneas or airway obstructions
occurred [48]. In a prospective study by Meyer et al. of
183 PS sessions, potentially serious complications were
desaturation <90% (5.4%) and laryngospasm (0.5%)
[47]. Both intravenously (IV) and intramuscularly (IM)
administered Ketamine were studied for PS in painful ED
procedures. In a recent meta-analysis of 8282 children
receiving PS with ketamine for procedures in an ED, the
overall incidence of respiratory adverse events was 3.9%.
Independent risk factors were high intravenous doses,
administration to children younger than 2 years or aged 13
yearsorolder,andtheconcomitantuseofanticholinergicsor
benzodiazepines. Variables without independent association
included oropharyngeal procedures, underlying physical
illness (American Society of Anesthesiologists class > or
=3), and the choice of intravenous versus intramuscular
route [30]. A retrospective analysis by Green et al. of a
series of cases (N = 636) in which sedation with ketamine
was administered by pediatric gastroenterologists for
gastrocopies in children, showed a high incidence of
laryngospasm (13.9% in the age group <6 years; 3.6% in the
age group >6y e a r s )[ 45].
Adverse Eﬀects of Dexmedetomidine. In the last few years,
dexmedetomidine has been studied for PS in children
undergoing painless procedures. Regarding eﬀectiveness for
sedation in diagnostic imaging dexmedetomidine is sig-
niﬁcantly superior to midazolam and similar to propofol
[49, 50]. Berkenbosch et al. published a prospective case
series reporting the use of Dexmedetomidine in 48 children.
Heart rate, blood pressure, and respiratory rate decreased
but remained within normal limits for age. End-tidal CO2
exceeded 50mmHg in seven of 404 measurements (1.7%)
[53]. Mason et al. studied dexmedetomidine for sedation for
computer tomography imaging (CT) in 62 patients. Heart
rate (HR) and mean arterial blood pressure decreased an
average of 15% and no signiﬁcant respiratory changes were
observed [54]. In another study (N = 250), these authors
showed that individual titration of dexmedetomidine for
CT imaging is associated with modest ﬂuctuations in HR
and blood pressure which were independent of age, required
no pharmacologic interventions, and did not result in any
adverse events [51]. In a prospective study by the same
group, dexmedetomidine as sole agent for pediatric MRI was
studied in 747 consecutive patients. Three diﬀerent dosing
groups were analysed. Bradycardia without hypotension
occurred in 16% of cases. There were no respiratory adverse
events [52] .R a ya n dT o b i a sr e t r o s p e c t i v e l yr e v i e w e dt h e
charts of 42 children with autism pervasive developmental
disorders and epilepsy, who received dexmedetomidine
for sedation during electroencephalography. No signiﬁcant
hemodynamic or respiratory eﬀects were noted [55]. In
two separate randomized controlled trials, Koroglu et al.
compared dexmedetomidine with respectively midazolam
and propofol for sedation in children undergoing MRI
scanning. No relevant adverse events were seen in the8 International Journal of Pediatrics
children sedated with dexmedetomidine (N = 70) [49,
50].
Adverse Eﬀects of Remifentanil. Remifentanil, a potent ultra-
short acting synthetic opioid, has been studied for PS in
children undergoing short painful procedures (e.g., lumbar
puncture, and bone marrow puncture), both as a sole agent
andcombinedwithMidazolamorPropofol.Litmanreported
a high incidence of potentially life threatening respiratory
depression in children undergoing painful procedures with
the combination of a benzodiazepine and remifentanil. Out
of 31 patients 25 (80.6%) developed an apnea, requiring
constant stimulation, and 10 (32.3%) became hypoxemic
[58] Keidan et al. published a randomized controlled trial
comparing propofol (N = 36) and propofol-remifentanil
(N = 41) for bone marrow aspiration in children. The
addition of remifentanil was associated with a decrease in
propofol dose and, consequently, recovery time, but with an
increased risk of respiratory depression: hypoventilation or
hypoxemia were signiﬁcantly more frequent if remifentanil
wasadded(19.5%versus11.1%)[56]Inarecentrandomized
controlled trial by Antmen et al.(A2), eighty children under-
going bone marrow aspiration were randomly assigned to
one of four sedation regimens: remifentanil 1mcg/kg (N =
20), midazolam 0.05mg/kg + remifentanil 0.5mcg/kg/min
(N = 20), alfentanil 20mcg/kg (N = 20), and midazolam
0.05mg/kg + alfentanil 20mcg/kg (N = 20). Relevant
adverse events occurred in none of the 4 groups [62].
Adverse Eﬀects of Nitrous Oxide. A French multicentric
prospective study by Gall et al. of 7,511 sedation sessions
with 50% nitrous oxide/50% oxygen premix, investigated the
incidenceofseriouscomplications(oxygendesaturation,air-
way obstruction, apnea, bradycardia and/or oversedation).
Such complications occurred in 25 sessions (0.3%). In all
cases, the problems dissolved instantly after discontinuation
of the administration of nitrous oxide, without any need
for airway intervention or ventilation. The main risk factors
were age (<1 year) and the simultaneous administration of
benzodiazepines and opiates [31].
Zier et al. reported a case series of 1018 sedation sessions
using nurse-administered nitrous oxide (continuous ﬂow;
concentration of 70%) for urinary catheterization. Only
minor adverse events (diaphoresis, nausea, and vomiting)
were observed in 4% of the sessions. Oversedation without
respiratory compromise occurred in 0.8% of cases [61]. Babl
et al. studied prospectively the relationship between fasting
status and adverse events in 220 patients receiving nitrous
oxide in a pediatric ED. Fasting status was obtained in 218
patients (99.1%). Of these, 155 (71.1%) did not meet fasting
guidelines for solids. There were no serious adverse events
and no episodes of aspiration. Emesis occurred in 7% of
cases. There was no signiﬁcant diﬀerence in median fasting
time between patients with and without emesis [59].
The same author studied prospectively the safetyof high-
concentration continuous-ﬂow nitrous oxide (70% versus
50%) in children (N = 762, age range 1–17 yrs). Sixty-three
(8.3%) patients sustained mild and self-resolving adverse
events, most of which were vomiting (5.7%); 2 patients
(0.2%) had serious adverse events. Both serious events (1
chest pain and 1 desaturation) occurred in the group of 70%
nitrous oxide. There was no signiﬁcant diﬀerence in adverse
events rates between nitrous oxide 70% (8.4%) and nitrous
oxide 50% (9.9%) [60].
3.1.3. Data from Literature on the Predictability and Control-
labilityofSedationDepth. Ithasbeenshownthatunexpected
deep sedation is associated with a higher rate of adverse
events [13, 21]. The predictability of ﬁnal sedation levels of a
certain drug therefore determines the skills and competence
the professionals in charge should possess. A search was
made of existing literature on this subject. Results are
summarized in Table 3.
Motas et al. published an observational study in 86
children who underwent PS using midazolam, midazolam
in combination with fentanyl or pethidine, chloral hydrate,
pentobarbital, or ketamine. Sedation depth was assessed
by an independent observer, using a validated sedation
scale and by bispectral cerebral function monitoring (BIS).
These observations were compared to the sedation depth the
practitioners set out to achieve. The intended sedation depth
was reached in 72% (sedation scale) and in 52% (BIS) of
the cases, respectively. In 35% of the cases, the BIS ﬁgure
presentwasconsistentwithgeneralanesthesia.Theincidence
of airway complications was signiﬁcantly higher in the group
that had been deeply sedated unintentionally [21].
A risk assessment by Hoﬀman et al. based on prospective
collected data of 96 sedations for widely varying procedures
with chloral hydrate (15%), midazolam (28%), fentanyl
(1%), pentobarbital (28%), ketamine (2.8%), or cocktails of
3ormoreofthemedicines(5.7%),showedthatin22%ofthe
procedures, a deep sedation level was reached, although deep
sedation had only been intended in 7% of the procedures
[13].
Malviya et al. studied two diﬀerent types of discharge
criteria in 29 children who had been sedated for an
echocardiography (27/29 = 93.1% with chloral hydrate and
2/29 = 6.9% with midazolam + diphenhydramine). Standard
criteria (normal vital parameters, normal oxygen saturation,
return to original consciousness level, normal cough and
swallowing reﬂexes, and normal movement) were compared
with an objective assessment of the consciousness using BIS
monitoring and two validated scales of observation. The
objective criteria correlated better with being fully awake
than the standard criteria but it took signiﬁcantly more time
before those objective criteria were reached [63].
The under 1.2 cited study by Newman et al. (prospective
studyof1341PSsessionsinchildreninanemergencydepart-
ment (ED)) showed an incidence of serious complications of
11.9% of which 92% occurred during the actual procedure,
whereas the rest occurred after the procedure up to 40
minutes after the last administered dose of sedative [34].
3.2. Requisite Skills and Competences to Guarantee Optimal
Eﬀectiveness. Eﬀectiveness is named as an outcome measure
in most of the studies on PS published over the lastInternational Journal of Pediatrics 9
Table 3: Conclusions regarding predictability and controllability of nontitratbale drugs intended for PS.
Nr Conclusion Quality Level
(1)
For a PS with medicines that are diﬃcult to titrate and/or long-acting (e.g., chloral hydrate, midazolam,
barbiturates, opiates or combinations), the eventual depth of sedation, eﬀectiveness and duration of the
sedation and timing of adverse events cannot reliably be predicted. Therefore, possible adverse eﬀects of any
possible sedation depth should always be anticipated in terms of recognition and treatment.
Level 2
(B) Hoﬀman et al. 2002 [13], Newman et al. 2003 [34], Malviya et al. 2004 [63], Motas et al. 2004 [21]
few decades. Mutual comparisons or combining averages
is impossible, because the deﬁnition of eﬀectiveness varies
considerably for each procedure, or because it is not properly
deﬁned at all. No prospective controlled studies were found
comparing diﬀerent levels of professional skills/competence
and the eﬀectiveness of PS. Evidence was therefore searched
in an indirect way by looking for which PS techniques
a professional should master in order to achieve optimal
PS eﬀectiveness. We deﬁned that an optimal PS technique
should achieve near 100% predictable procedural success and
timing, an optimal match between desired and achieved
levels of sedation, minimal induction and recovery times,
and an optimal patient comfort by minimizing procedural
pain, anxiety and the need for physical immobilization or
restraint. Next, we looked for settings and techniques with
published evidence for contributing in reaching this optimal
level. Results were classiﬁed as conclusions in four diﬀerent
categories of techniques or strategies with a proven eﬀect on
PS eﬀectiveness.
3.2.1. Eﬀect of the Introduction of a Dedicated Well-Trained
Team for PS on the Eﬀectiveness of PS. Several authors
have shown that the introduction of a dedicated PS team
that works according to published guidelines results in a
signiﬁcant decrease of procedural failure (Level 2 conclusion
based on Hoﬀman et al. 2002(B), Ruess et al. 2002(C), and
Sury et al. 1999(C)) [13, 15, 64]. Although it is impossible
to deduce from those studies to what extent this result
is due to speciﬁc professional skills and competence, PS
seems to become more eﬀective when speciﬁcally trained
professionals perform PS in accordance with international
guidelines.
3.2.2. The Superiority of Titratable Medicines or Medicines
with a Highly Predictable Eﬀectiveness, Including Deep Seda-
tion. In order to achieve an optimal level of eﬀectiveness,
each PS should ideally be directed to an individually
determined sedation level. This makes the use of short acting
drugs (e.g., propofol) that can be titrated to the desired level
of sedation (including deep sedation) advantageous over the
use of long acting drugs. There is growing evidence for
the need for deep sedation for the majority of procedures
in pediatrics. A retrospective analysis by Dial et al. of the
sedation depth that was eventually required for a category
of examinations (N = 32) that were not (very) painful and
for which immobility was not strictly required turned out
to be deep sedation after all in 26/32 cases (81.3%). For the
categoryofpainfulandinvasiveexaminationsforwhichlocal
anesthesia was used, light to moderate sedation turned out
to be suﬃcient in only 4/156 cases (2.6%), whereas deep
sedation was necessary in 136/156 cases (87.2%) and even a
generalanesthesiain16/156cases(10.3%)[24].Ontheother
hand there is good evidence for the superior eﬀectiveness
of PS with titratable medicines with a clearly predictable
eﬀectiveness. This has been demonstrated in children under-
going very painful procedures (e.g., oncological procedures,
procedures in an ED), (protracted) stressful procedures (e.g.,
endoscopies) and procedures for which patients need to lie
still for long periods (e.g., for imaging and radiotherapy). In
addition, working with propofol also leads to a signiﬁcantly
shorter induction time and a signiﬁcantly quicker recovery.
Having the requisite competencies and skills to use this sort
of sedatives safely therefore seems important to guarantee
optimal eﬀectiveness (Level 1 conclusion b a s e do nM i g i t ae t
al. 2006(A1), Marx et al. 1997(A2), Pershad et al. 2007(A2),
Dalal et al. 2006(B), Seiler et al. 2001(B), Iannalﬁ et al.
2005(B), Kohsoo et al. 2003(B), and Holdsworth et al.
2003(B)) [65–71].
3.2.3.DeployabilityofTechniquesforLightSedation. Children
often have to be physically forced or restrained for so-called
“minor painful procedures” (e.g., blood sampling, inserting
an intravenous access, suturing a wound, lumbar puncture,
bone marrow puncture, changing a dressing, incision of
abscess, resection of naevus or cyst, bladder catheterization,
intraarticular injection, and Ear Nose Throat procedures). It
has been demonstrated that the level of comfort during such
interventions can be considerably improved when nitrous
oxide is used. Nitrous oxide in concentrations of up to
70%, when combined with nonpharmacological distraction
techniques and adequate topical anesthesia, is a very eﬀective
and safe way to suppress procedural pain and stress in
children >1y e a ro l d .( Level 3 conclusion based on Iannalﬁ
et al. 2005(B), Kanagasundaram et al. 2001(C), Burnweit
et al. 2004(C), Frampton et al. 2003(C), and Zier et al.
2007(C) [61, 72–75]. For children undergoing reduction
of an uncomplicated forearm reduction nitrous oxide in
concentrations of 50% in combination with local anesthetics
is equally eﬀective as intravenous ketamine but is associated
with a signiﬁcantly shorter recovery time and less respiratory
side eﬀects. (Level 3 conclusion based on Luhmann et al.
2006(B)) [76]. In children that need to receive sutures,
nitrous oxide in concentrations of 50% in combination with
localanestheticscontrolstheproceduralpainandstressmore
eﬀectively than orally taken midazolam or local anesthetics
alone (Level 2 conclusion based on Luhmann et al. 2001(B)
and Bar-Meir et al. 2006(B)) [77, 78]. Inserting a venous
access in children who are known to have diﬃcult veins is10 International Journal of Pediatrics
easier under sedation with nitrous oxide + topical anesthesia
thantopicalanesthesiaalone.(Level3;Ekbometal.2005(B))
[79]. Topical anesthesia and nitrous oxide combined are
more eﬀective than topical anesthesia or nitrous oxide alone.
(Level 1 conclusion based on Paut et al. 2001(A2) and Hee et
al. 2003(A2)) [80, 81].
3.2.4. Use of Nonpharmacological Techniques. In literature,
good evidence is available for the importance of applying
nonpharmacological techniques to improve procedural suc-
cess and comfort. When a professional takes care over pro-
vidinggoodinformationabouttheproceduretobefollowed,
this may result in the children feeling less stress during the
procedure and being less scared about future procedures
(Level 3 conclusion based on Claar et al. 2002(C) and Bishop
et al. 2002(C)) [82, 83]. Adequate information also helps
parents to provide better support for their children during
a painful procedure (Level 3 conclusion based on Kupietzky
and Ram 2002(C) and Cline et al. 2006(D)) [84, 85]. A child
(>4y e a r so l d )t h a tr e c e i v e ss u ﬃcient preparation (e.g., by
information, practice, simulation, and play therapy) before
an MRI examination, a gastroscopy or nuclear examination
will experience less distress during the procedure and will
require less sedation or analgesia (Level 2 conclusion based on
Mahajan et al. 1998(A2), Rosenberg et al. 1997(B), Presdee
et al. 1997(C), Awogbemi et al. 2005(C), and de Amorim e
Silva et al. 2006(C)) [86–90]. Between 1993 and 2009 3 high-
quality Systematic Reviews (SR) of nonpharmacological
interventions for procedure-related pain in children have
been published, allowing 3 Level 1 conclusions.C e p e d ae t
al. (2006; A1 including 51 RCT’s of which only 4 addressed
proceduralpaininchildren)couldnotdemonstrateevidence
for the eﬀectiveness of music therapy during intravenous
cannulation and vaccination in children. Although listening
to music reduced pain intensity scales in general and opioid
requirements in particular, the reported eﬀects are small.
Pooling of the 4 studies was impossible due to diﬀerent
quantiﬁcation methods of pain intensity [91]. Richardson et
al. published a SR (2006; A1 including 7 RCTs and 1 non-
RCT) on the pain reducing eﬀects of hypnosis in pediatric
cancer patients undergoing common painful procedures
(infusapostaccess,venipuncture,lumbarpuncture,andbone
marrow aspiration). Although 7/8 studies included reported
a signiﬁcant reduction of pain, the authors conclude that
due to methodological limitations there is no conclusive
evidence for a signiﬁcant eﬀect of hypnosis on procedure-
related pain [92]. Finally, the SR by Uman et al. (2006; A1
including 28 trials) showed a signiﬁcant eﬀect of distraction
and hypnosis on self-reported pain during needle-related
procedures (intramuscular injection, vaccination, venipunc-
ture, intravenous cannulation, lumbar punction, and bone
marrow aspiration). For other psychologhical techniques
no signiﬁcant eﬀect on procedure-related pain could be
concluded [93].
An additional SR by Kleiber and Harper (1999) focused
on the eﬀects of distraction on self-reported pain in children
during intravenous cannulation, lumbar punction, bone
marrow aspiration, injection, venipuncture, dental proce-
dures, and burn treatment. They showed that distraction
causes a signiﬁcant reduction of self-reported pain. An
important limitation of this SR is the fact that no details
are provided on the methodological quality of the included
studies [94]. None of the SR could demonstrate any adverse
events of nonpharmacological techniques.
Hypnosis on children reduces procedure-related pain
and distress more eﬀectively compared to local anesthesia
(venipunctureandlumbarpuncture;Level1conclusionbased
on three independent A2 studies by the same authors: Liossi
et al. 2009, Liossi et al. 2006, and Liossi and Hatira 2003),
to cognitive behavioral therapy or no therapy (bone marrow
aspiration; Level 2 conclusion based on Liossi and Hatira
1999(A2)), and to standard medical care including relaxation
exercises or play intervention (cystogram; Level 2 conclusion
based on Butler 2005(A2)) [95–99].
In conclusion, we found that a professional able to use
psychological techniques for distraction or hypnosis during
painful and/or stressful medical procedures may be able to
reduce the child’s procedural distress. Furthermore, the use
of psychological techniques intended to distract children
during a painful and/or stressful medical procedure reduces
the need for sedation (Level 2 conclusion b a s e do nH a r n e d
and Strain 2001(B) and Train et al. 2006(B)) [100, 101].
4. Discussion
This paper shows suﬃcient evidence to support the state-
ment that safety and eﬀectiveness of PS are signiﬁcantly
related to the level of professional skills and competence.
Although there are no prospective studies comparing the
eﬀect of diﬀerent levels of skills and competence on PS
related safety and eﬀectiveness, this systematic paper identi-
ﬁed in the relevant literature which competences and skills
a professional should possess or achieve in order to be
able to perform PS in children safely and eﬀectively. For
that purpose, we systematically summarized the results in
conclusionsclassiﬁedaccordingtothestrengthofevidenceof
the contributing papers. These conclusions can be translated
into recommendations on the general skills and competence
any professional entrusted with PS must have in order to
achieve optimal safety and eﬀectiveness (Tables 4 and 5).
Besides general recommendations, we formulated addi-
tional recommendations depending on the level of sedation.
Contrary to the generally accepted division between mild,
moderate, and deep sedation in most guidelines, we believe
that, based on the evidence, having diﬀerent levels of
monitoring and competence for moderate and deep sedation
is arbitrary and potentially dangerous. Ever since the ﬁrst
guideline on PS was published, authors have linked the level
of sedation with potential respiratory and cardiovascular
side eﬀects and by this with necessary safety precautions,
monitoring, and professional skills and competence [10].
Consequently, deﬁnitions were made for mild sedation,
moderate sedation (formerly called “conscious sedation”),
deep sedation, and anesthesia. Mild sedation, formerly called
“anxiolysis”, is typically the result of one standard dose of
midazolam or by the breathing of nitrous oxide (inspired
concentrationupto50%)[60].Higherdoses,orotherdrugs,International Journal of Pediatrics 11
Table 4: General recommendations on necessary skills and competence for achieving optimal PS related safety and eﬀectiveness in children.
Nr Recommendations
(1)
Knowledge of the drug dosing, dosing techniques, indications, contraindications, and requisite precautions of the sedation
technique used, acquired through speciﬁc training or demonstrable relevant experience.
(2) Regular personal experience of the applied medication or technique∗.
(3)
Applying the form of sedation that is most appropriate for the procedure and the patient. This implicates the ability to guarantee
the optimally eﬀective sedation level in a predictable manner. An optimal PS technique should achieve near 100% predictable
procedural success and timing, an optimal match between desired and achieved levels of sedation, minimal induction, and recovery
times and an optimal patient comfort by minimizing procedural pain, anxiety, and the need for physical immobilization or
restraint.
(4) The ability to perform preprocedural screening and a systematic risk analysis.
(5)
The ability to inform the patient, parents or carers about the sedation technique, the eﬀects, potential side eﬀects, and possible
alternatives. The information must be given in time and be appropriate for the comprehension level of the patient and
parents/carers.
(6)
The ability to guarantee a child-centered approach within a general policy that favors children before, during and after the
procedure.
(7)
The ability to apply, or arrange for complementary nonpharmacological techniques like preparation, distraction, combined
cognitive-behavioral interventions, and hypnosis.
(8)
The ability to (a) apply eﬀective local or topical anesthesia, if appropriate, and (b) to recognize and intervene with possible toxicity
of local anesthetic agents.
(9)
Organizing the necessary monitoring and rescue facilities during and after the procedure for as long as the consciousness level is
lowered.
(10) The ability to organize a supervised recovery phase and to deﬁne the discharge criteria.
(11) The ability to organize the prompt availability of a resuscitation team or a professional trained in Pediatric Life Support.
(12) Supervising, registering, assessing and optimizing the quality of the sedation in terms of safety and eﬀectiveness.
∗It is impossible to derive from literature a more precise deﬁnition of “regular personal experience”. The authors believe that regular experience means a
minimal of 50 PS sessions per year.
either alone or in combination, are likely to cause deeper
levels of sedation. Commonly used PS drugs intended for
moderate sedation such as chloral hydrate, barbiturates,
benzodiazepines with/without opioids, and solely opioids
cause wide variations in depth of sedation. If a single dose
is given the goal of moderate sedation is not achieved or
exceeded in a substantial number of children. Therefore,
for individual cases, prediction of the eﬀective sedation end
point is unreliable [21]. Multiple doses or combinations
of drugs are more likely to cause deep sedation and are
associated with hypoventilation, respiratory depression, and
serious morbidity. Considering sedation levels as a sliding
scale, rather than a step-by-step change in consciousness,
the transition from one level to another can be subtle and
sudden. It is, therefore, advisable to recommend the same
safety precautions and professional skills for all levels of
sedation beyond mild sedation, irrespective of the drug used
for PS. Consequently, it is wise to formulate separate rec-
ommendations regarding professional skills and competence
for mild sedation on one hand and for moderate to deep
sedation on the other hand (Tables 5(a) and 5(b)). Although
the safety proﬁles of PS drugs are clearly diﬀerent, the
likelihoodthatpotentiallyseriousadverseeventsmayhappen
and the predictability of depth and duration of sedation are
c l e a r l ym o r ei m p o r t a n t .B o t hi s s u e sh a v ead i r e c ti m p a c to n
the imperative skills and competence, mainly in terms of
timely recognition and appropriate management of possible
adverse events. PS-related safety is determined by logistics,
organization and professional skills rather than by speciﬁc
pharmacologic characteristics.
I no r d e rt oa c h i e v ea no p t i m a ll e v e lo fe ﬀectiveness,
each PS should ideally be directed to an individually
determined sedation level. This makes the use of short-
acting “titratable” drugs advantageous over the use of long-
acting drugs. Short-acting drugs can be used to overcome
the pain and distress that varies according to the procedures
and the patients themselves. It can be concluded from this
systematic paper that professionals having the requisite skills
and competence to work with titratable anesthetics (e.g.,
propofol) are able to achieve more optimally an eﬀective
PS for children undergoing very painful procedures (e.g.,
oncological procedures, procedures in an ED), (protracted)
stressful procedures (e.g., endoscopies) and procedures for
which patients need to lie still for long periods (e.g.,
diagnostic imaging and radiotherapy). In particular, young
children (<6 years) are in need of deep sedation sometimes
even for so called “mild” procedures [23, 24]. Although
the obvious advantages of titratable deep sedation (e.g.,12 International Journal of Pediatrics
Table 5
(a) Recommended speciﬁc additional skills and competence for achieving optimal safety during moderate and deep sedation in children.
Nr Recommendations
(1) In order to guarantee optimal levels of safety and eﬀectiveness during a PS involving (a possibility of) moderate-to-deep
sedation, the PS must be carried out by a separate professional that is not involved in the actual procedure.
(2)
During a PS involving (a possibility of) moderate or deep sedation and during the subsequent recovery phase, a professional
must be present with at least the following additional competence and skills:
(1) The ability to assess and interpret the sedation depth.
(2) The ability to guarantee the necessary monitoring of vital parameters, including capnography, and being able to appraise
and interpret the monitored information.
(3) Having acquired the necessary knowledge during a specialist course and by means of refresher courses and ability to manage
the following techniques at APLS∗ level:
(3.1) Techniques intended to guarantee an open airway, including skills to manage larynx spasm and to use Laryngeal
Mask Airways.
(3.2) Techniques to administer mask/bag ventilation.
(3.3) The use of antagonists.
(3.4) Heart massage techniques.
∗APLS: Advanced Pediatric Life Support.
(b) Speciﬁc additional skills and competence for achieving optimal safety during mild sedation/anxiolysis in children.
Nr Recommendations
(1)
During a PS involving mild sedation and during the subsequent recovery phase, a professional must be present with the at least
the following additional competence and skills:
(1) The ability to assess and interpret the sedation depth.
(2) The ability to maintain continuous verbal contact with the patient in the absence of any other form of monitoring.
(3) Having acquired the necessary knowledge through a specialist course and by means of refresher courses and the ability to
manage the following techniques at BLS∗ level:
(3.1) Techniques intended to guarantee an open airway.
(3.2) Techniques to administer mask/bag ventilation.
∗BLS: Basic Life Support.
using propofol) over other sedatives for many procedures
in children are increasingly emphasized in recent literature,
the term deep sedation has been under discussion, because
it may be indistinguishable from general anesthesia. While
this point may be overstated it has led to the widespread
recommendation that the same personnel, equipment, and
facilities must be available to manage both deep sedation
and anesthesia. The most important severe adverse eﬀect
of propofol is respiratory depression, which is associated
with unexpected deep sedation and can arise suddenly and
unexpectedly [1]. As a consequence the question whether
nonanesthesiologists can be safely entrusted with the use
of this potent drug has been a matter of debate [23].
There is an obvious reluctance by the anesthetic world
to entrust trained non-anesthesiologist with highly active
anesthetic drugs [23, 102]. However, in many countries, a
clear trend is seen to entrust deep sedation to speciﬁcally
trained non-anesthesia professionals in particular because
of the scarcity of anesthesiologists. Emergency physicians,
intensivists and gastroenterologists have been prominent in
thisdevelopment[12,29,40,41,102,103].Inaddition,Ithas
beenshownthatinoptimalsafetyandmonitoringconditions
deep sedation using propofol is equally safe irrespective
whether it is administered by trained nonanesthesiologists
or anesthesiologists [26, 102]. An evidence-based clinical
practice advisory for the administration of propofol for PS
by nonanesthesiologists was recently published [104].
For minor painful procedures the deployability of short-
acting mild sedation using nitrous oxide and ability to apply
adequate topical anesthesia are essential skills for optimal
eﬀectiveness. In addition, not only the ability to deﬁne and
apply an individually tailored PS technique but also the
ability to implement nonpharmacological techniques, such
as distraction, hypnosis and combined cognitive-behavioral
interventions, belongs to the essential competence and skills.
Finally, we found evidence that the application of
published guidelines within a well organized, well trained,
and dedicated PS team will enhance PS related safety and
eﬀectiveness.
In conclusion, PS has to be considered as a separate
medicalact,providedbywell-trained,competent,andskilled
professionals only, working within a context of transparency,
registration, and ongoing quality control. Skills and com-
petence, rather than professional title, are determinants for
safe and eﬀective PS. We believe that these evidence-based
recommendationsregardingnecessaryskillsandcompetenceInternational Journal of Pediatrics 13
should be used to set up training programs and to deﬁne
which professionals can and cannot be credentialed for PS in
children.Muchemphasisisneededforadequateandeﬀective
implementation strategies for these recommendations.
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